Cullinan Therapeutics, Inc.
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
CGEM | NDAQ
Overview
Corporate Details
- ISIN(s):
- US2300311063
- LEI:
- Country:
- United States of America
- Address:
- ONE MAIN STREET, 2142 CAMBRIDGE
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of high-impact, differentiated therapies for autoimmune diseases and cancer. The company leverages deep expertise in immune modulation to discover and advance potential first-in-class or best-in-class molecules. Its strategy involves a deliberate and rigorous selection process to progress only the most promising candidates that address significant unmet medical needs. By combining scientific expertise with strategic risk-taking, Cullinan aims to accelerate the development of therapies that provide meaningful outcomes for patients and establish new standards of care.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cullinan Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cullinan Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cullinan Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
